Skip to main
EXEL

Exelixis (EXEL) Stock Forecast & Price Target

Exelixis (EXEL) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 38%
Buy 19%
Hold 44%
Sell 0%
Strong Sell 0%

Bulls say

Exelixis Inc has demonstrated strong momentum with its Cabometyx product, particularly in first-line renal cell carcinoma (RCC) and expanding presence in second-line neuroendocrine tumors (NET), supported by a robust growth acceleration. The company's strategic expansion of its gastrointestinal sales team aims to enhance Cabometyx's market share and prepare for the anticipated launch of zanzalintinib in colorectal cancer (CRC), further bolstering its portfolio. Financial projections for Cabometyx sales have been slightly increased for the fiscal years 2026 through 2028, from $2,343 million to $2,352 million in FY26, indicating a strong and sustainable profitability trajectory for the company.

Bears say

Exelixis Inc. has reported a decline in its gross-to-net (GTN) percentage, dropping from 30.2% to 28.5% in the fourth quarter of 2025, primarily due to lower PHS/340B volume, raising concerns about revenue stability. Additionally, Cabometyx sales remained flat sequentially at $545 million, falling short of both internal and consensus estimates, which compounds worries about its growth potential in an increasingly competitive market. The company faces significant risks, including commercial challenges related to Cabometyx, potential unfavorable clinical data from ongoing programs, and the threat of generic competition eroding its existing franchises.

Exelixis (EXEL) has been analyzed by 16 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 19% recommend Buy, 44% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exelixis (EXEL) Forecast

Analysts have given Exelixis (EXEL) a Buy based on their latest research and market trends.

According to 16 analysts, Exelixis (EXEL) has a Buy consensus rating as of Apr 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exelixis (EXEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.